GMEB2: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Target Name: GMEB2

NCBI ID: G26205

GMEB2

GMEB2: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

GMEB2 (Growth-modifying gene-expression-based 2) is a non-coding RNA molecule that has been identified as a potential drug target (PIF p79) and a biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. In this article, we will discuss the biology of GMEB2, its potential drug targets, and its potential as a biomarker for disease.

Background:
GMEB2 is a non-coding RNA molecule that is expressed in various tissues and cells of the body. It has been shown to play a role in regulating gene expression and has been associated with various diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

Potential Drug Targets:
GMEB2 is a potential drug target due to its unique biology and the involvement of various signaling pathways. One of the primary targets of GMEB2 is the PI3K/Akt signaling pathway, which is involved in cell survival, proliferation, and angiogenesis. Activation of this pathway has been shown to promote the growth and survival of various cancer cells, making it a potential target for cancer treatments. Additionally, GMEB2 has also been shown to play a role in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, by regulating the expression of genes involved in neurotransmitter synthesis and release.

Biomarker Potential:
GMEB2 has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. The expression of GMEB2 has been shown to be downregulated in various diseases, including cancer, and its expression has been shown to be increased in neurodegenerative diseases. This suggests that GMEB2 may be a useful biomarker for the diagnosis and prognosis of these diseases. Additionally, the downregulation of GMEB2 expression in neurodegenerative diseases may also be a potential target for therapeutic intervention.

Function and Interaction:
GMEB2 is a non-coding RNA molecule that plays a central role in the regulation of gene expression. It has been shown to interact with various proteins, including the PI3K/Akt signaling pathway. This interaction between GMEB2 and the PI3K/Akt pathway suggests that GMEB2 may be involved in the regulation of cellular processes that are dependent on the PI3K/Akt signaling pathway, such as cell survival, proliferation, and angiogenesis.

Conclusion:
In conclusion, GMEB2 is a non-coding RNA molecule that has been identified as a potential drug target (PIF p79) and a biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. The unique biology and involvement of various signaling pathways make GMEB2 an attractive target for therapeutic intervention. Further research is needed to fully understand the role of GMEB2 in disease and to develop effective treatments.

Protein Name: Glucocorticoid Modulatory Element Binding Protein 2

Functions: Trans-acting factor that binds to glucocorticoid modulatory elements (GME) present in the TAT (tyrosine aminotransferase) promoter and increases sensitivity to low concentrations of glucocorticoids. Binds also to the transferrin receptor promoter. Essential auxiliary factor for the replication of parvoviruses

The "GMEB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GMEB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets